Pathologic complete response following neoadjuvant administration of HER2-targeted therapies is a reliable surrogate for favorable long-term outcomes in HER2pos BC [7, 8]; in fact, the Food and Drug Administration (FDA) supports pCR as a trial endpoint for drug approval [20]. This evidence concerns the gene ERBB2 and breast cancer.